$CMPS
COMPASS Pathways plc Stock $cmps

$cmps Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017390 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.587M	$10.56M	$6.964M
YoY Change	19.72%	51.65%	37.63%
% of Gross Profit
Research & Development	$19.82M	$19.04M	$15.36M
YoY Change	24.48%	23.91%	123.16%
% of Gross Profit
Depreciation & Amortization	$110.0K	$48.00K	$100.0K
YoY Change	10.0%	-52.0%	185.71%
% of Gross Profit
Operating Expenses	$29.41M	$31.79M	$25.42M
YoY Change	7.88%	25.05%	86.88%
Operating Profit	-$32.66M	-$31.79M	-$25.42M
YoY Change	19.84%	25.05%	86.88%
Interest Expense	$1.376M	$2.685M	$1.333M
YoY Change	-29.72%	101.43%	-308.28%
% of Operating Profit
Other Income/Expense, Net	$3.147M	$7.710M	$4.389M
YoY Change	-49.85%	75.67%	379.67%
Pretax Income	-$28.14M	-$24.08M	-$21.03M
YoY Change	34.13%	14.49%	65.77%
Income Tax	$194.0K	$130.0K	$140.0K
% Of Pretax Income
Net Earnings	-$28.34M	-$24.21M	-$21.17M
YoY Change	34.69%	14.35%	66.5%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.62	-$0.57	-$0.50
Diluted Earnings Per Share	-$0.62	-$0.57	-$0.50
COMMON SHARES
Basic Shares Outstanding	45.62M shares	42.76M shares	42.04M shares
Diluted Shares Outstanding	45.57M shares	42.73M shares	42.04M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.2M	$117.1M	$243.7M
YoY Change	-28.45%	-51.94%	35.76%
Cash & Equivalents	$148.2M	$117.1M	$243.7M
Short-Term Investments
Other Short-Term Assets	$22.35M	$1.490M	$1.334M
YoY Change	2250.16%	11.69%	-82.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$193.6M	$167.8M	$266.6M
YoY Change	-16.55%	-37.04%	36.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.266M	$612.0K	$415.0K
YoY Change	673.27%	47.47%	38.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$469.0K	$469.0K	$508.0K
YoY Change	-0.21%	-7.68%	1.6%
Other Assets	$10.50M	$212.0K	$334.0K
YoY Change	2460.49%	-36.53%	11.33%
Total Long-Term Assets	$16.23M	$5.484M	$5.545M
YoY Change	144.4%	-1.1%	454.5%
TOTAL ASSETS
Total Short-Term Assets	$193.6M	$167.8M	$266.6M
Total Long-Term Assets	$16.23M	$5.484M	$5.545M
Total Assets	$209.8M	$173.3M	$272.1M
YoY Change	-12.07%	-36.31%	38.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.982M	$3.875M	$2.054M
YoY Change	-40.91%	88.66%	-61.25%
Accrued Expenses	$10.09M	$6.707M	$8.461M
YoY Change	10.22%	-20.73%	370.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.78M	$11.25M	$11.68M
YoY Change	-3.46%	-3.65%	53.68%
LONG-TERM LIABILITIES
Long-Term Debt	$28.12M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.539M	$412.0K	$843.0K
YoY Change	210.39%	-51.13%
Total Long-Term Liabilities	$30.66M	$412.0K	$843.0K
YoY Change	3648.53%	-51.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.78M	$11.25M	$11.68M
Total Long-Term Liabilities	$30.66M	$412.0K	$843.0K
Total Liabilities	$43.44M	$11.67M	$12.52M
YoY Change	209.15%	-6.84%	64.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$313.7M	-$285.4M	-$190.8M
YoY Change	48.08%	49.55%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$166.4M	$161.6M	$259.6M
YoY Change
Total Liabilities & Shareholders Equity	$209.8M	$173.3M	$272.1M
YoY Change	-12.07%	-36.31%	38.75%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$28.34M	-$24.21M	-$21.17M
YoY Change	34.69%	14.35%	66.5%
Depreciation, Depletion And Amortization	$110.0K	$48.00K	$100.0K
YoY Change	10.0%	-52.0%	185.71%
Cash From Operating Activities	-$24.81M	-$27.72M	-$23.12M
YoY Change	37.81%	19.89%	67.83%
INVESTING ACTIVITIES
Capital Expenditures	$19.00K	$29.00K	$82.00K
YoY Change	-104.61%	-64.63%	17.14%
Acquisitions
YoY Change
Other Investing Activities	$2.000K
YoY Change
Cash From Investing Activities	-$17.00K	-$29.00K	-$82.00K
YoY Change	-95.87%	-64.63%	17.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	55.93M	$1.079M	$189.0K
YoY Change	26157.75%	470.9%	-80.27%
NET CHANGE
Cash From Operating Activities	-24.81M	-$27.72M	-$23.12M
Cash From Investing Activities	-17.00K	-$29.00K	-$82.00K
Cash From Financing Activities	55.93M	$1.079M	$189.0K
Net Change In Cash	31.10M	-$26.01M	-$29.56M
YoY Change	-270.84%	-12.02%	173.52%
FREE CASH FLOW
Cash From Operating Activities	-$24.81M	-$27.72M	-$23.12M
Capital Expenditures	$19.00K	$29.00K	$82.00K
Free Cash Flow	-$24.83M	-$27.75M	-$23.21M
YoY Change	41.15%	19.59%	67.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001816590
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39522
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	COMPASS Pathways plc
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	33 Broadwick Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	W1F 0DQ
CY2023Q1	dei	Entity Address Country EntityAddressCountry	GB
CY2023Q1	dei	City Area Code CityAreaCode	716
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	676-6461
CY2023Q1	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing one ordinary share, par value of £0.008 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CMPS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45621678	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117103000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143206000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	271000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	175000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	71000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	575000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	50381000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	47695000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	167826000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	191651000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	469000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	469000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	612000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	617000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1593000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2006000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2598000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2224000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	212000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	327000	usd
CY2023Q1	us-gaap	Assets Assets	173310000	usd
CY2022Q4	us-gaap	Assets Assets	197294000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3875000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4761000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6267000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9325000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1112000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1510000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11254000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15596000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	412000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	418000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11666000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	16014000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	463973000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	458825000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17445000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16867000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-285354000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-261146000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	161644000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	181280000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	173310000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	197294000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19035000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15362000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12753000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10058000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	31788000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	25420000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31788000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25420000	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	709000	usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	134000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2685000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1333000	usd
CY2023Q1	cmps	Research And Development Tax Credit Income Tax Expense Benefit ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit	-4316000	usd
CY2022Q1	cmps	Research And Development Tax Credit Income Tax Expense Benefit ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit	-2922000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7710000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4389000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24078000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21031000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	140000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21171000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-578000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7193000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24786000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28364000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42725863	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42725863	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42036563	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42036563	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	284412000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	397000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3128000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-7193000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21171000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	259574000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	181280000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1188000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	109000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4071000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-578000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	161644000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21171000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	54000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2107000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	219000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4071000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3128000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	539000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	550000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1484000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1386000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-129000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	135000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	44000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	311000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-478000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-538000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-973000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-445000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3216000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2650000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27723000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23123000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1188000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	109000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	189000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1079000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	189000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6543000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26007000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29559000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143381000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273347000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117374000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243788000	usd
CY2023Q1	cmps	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities Including Initial Adoption RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption	92000	usd
CY2022Q1	cmps	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities Including Initial Adoption RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption	0	usd
CY2023Q1	cmps	Proceeds From Stock Options Exercised Not Received ProceedsFromStockOptionsExercisedNotReceived	0	usd
CY2022Q1	cmps	Proceeds From Stock Options Exercised Not Received ProceedsFromStockOptionsExercisedNotReceived	208000	usd
CY2023Q1	cmps	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	0	usd
CY2022Q1	cmps	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	835000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117103000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	243684000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	271000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	104000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117374000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243788000	usd
CY2021Q4	cmps	Number Of Ordinary Shares Conversion Ratio NumberOfOrdinarySharesConversionRatio	1
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24200000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21200000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117100000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div>
CY2023Q1	cmps	Number Of Geographic Regions NumberOfGeographicRegions	2	region
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	cmps	Research And Development Expenditures Tax Credit Connected Parties Maximum Percentage Of Total Claim ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim	0.15
CY2023Q1	cmps	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	18672000	usd
CY2022Q4	cmps	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	13972000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1755000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2818000	usd
CY2023Q1	cmps	Prepaid Expense Research And Development Current PrepaidExpenseResearchAndDevelopmentCurrent	26775000	usd
CY2022Q4	cmps	Prepaid Expense Research And Development Current PrepaidExpenseResearchAndDevelopmentCurrent	28211000	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1689000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1652000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1490000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1042000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50381000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	47695000	usd
CY2023Q1	cmps	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1815000	usd
CY2022Q4	cmps	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1684000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	803000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1284000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2976000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5534000	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	167000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	672000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	656000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6267000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9325000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.55
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M17D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	13013000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2076950	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.08
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3790	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.01
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	131350	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	24.13
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7034542	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.25
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M17D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	17648000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2600262	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.86
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M10D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15048000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4434280	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	14.65
CY2023Q1	cmps	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm	P9Y3M7D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	2600000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.27
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.38
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	42300000	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	35200000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8712
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8020
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0347
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0165
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	cmps	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice	10.85
CY2022Q1	cmps	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice	15.98
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4071000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3128000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24208000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21171000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24208000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24208000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21171000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21171000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42725863	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42725863	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42036563	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42036563	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7442071	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4756183	shares
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	573000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	560000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	87000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	86000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	660000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	646000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	562000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	578000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	102000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0601
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0467
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1058000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	271000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	223000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	55000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1607000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1524000	usd

Files In Submission

Name	View Source	Status
cmps-20230331_pre.xml	Edgar Link	unprocessable
0001628280-23-017390-index-headers.html	Edgar Link	pending
0001628280-23-017390-index.html	Edgar Link	pending
0001628280-23-017390.txt	Edgar Link	pending
0001628280-23-017390-xbrl.zip	Edgar Link	pending
cmps-20230331.htm	Edgar Link	pending
cmps-20230331.xsd	Edgar Link	pending
cmps-q1x23xex311ceo302cert.htm	Edgar Link	pending
cmps-q1x23xex312cfo302cert.htm	Edgar Link	pending
cmps-q1x23xex321ceoxcfosec.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
foraresidentagreement.htm	Edgar Link	pending
foraresidentagreement001.jpg	Edgar Link	pending
foraresidentagreement002.jpg	Edgar Link	pending
foraresidentagreement003.jpg	Edgar Link	pending
foraresidentagreement004.jpg	Edgar Link	pending
foraresidentagreement005.jpg	Edgar Link	pending
foraresidentagreement006.jpg	Edgar Link	pending
foraresidentagreement007.jpg	Edgar Link	pending
foraresidentagreement008.jpg	Edgar Link	pending
foraresidentagreement009.jpg	Edgar Link	pending
foraresidentagreement010.jpg	Edgar Link	pending
foraresidentagreement011.jpg	Edgar Link	pending
foraresidentagreement012.jpg	Edgar Link	pending
foraresidentagreement013.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
cmps-20230331_cal.xml	Edgar Link	unprocessable
cmps-20230331_def.xml	Edgar Link	unprocessable
cmps-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cmps-20230331_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CMPS
COMPASS Pathways plc Stock $cmps

2023 Q2 Form 10-Q Financial Statement

#000162828023017390 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPS COMPASS Pathways plc Stock $cmps

2023 Q2 Form 10-Q Financial Statement

#000162828023017390 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPS
COMPASS Pathways plc Stock $cmps